EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate

Nassim Vibert, Vérane Achard, Pierre Pouvreau, Constance Huck, Jonathan Khalifa, Paul Sargos

Cancer/Radiothérapie · 2025

DOI: 10.1016/j.canrad.2025.104665 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer/Radiothérapie, 2025. Verfasst von Nassim Vibert und 5 weiteren Autor:innen. Beteiligte Einrichtung: Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France. Electronic address: n.vibert@bordeaux.unicancer.fr. Hauptthemen laut MEDLINE: Gynecomastia, Prostatic Neoplasms, Androgen Antagonists, Androgen Receptor Antagonists. Die Arbeit nennt 57 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This review aims to evaluate the incidence, clinical impact, and available therapeutic options for the management of gynecomastia induced by hormonal therapy, particularly in the era of androgen receptor pathway inhibitors, in patients with prostate cancer. We analysed data from clinical trials evaluating the incidence of gynecomastia under androgen receptor pathway inhibitors and the efficacy of both prophylactic and curative strategies, primarily tamoxifen and male breast radiotherapy, in patients receiving bicalutamide. Androgen receptor pathway inhibitors monotherapy is associated with high rates of gynecomastia (34 to 55 %), whereas combining androgen receptor pathway inhibitors with chemical castration significantly reduces this risk. Prophylactic tamoxifen significantly decreases gynecomastia incidence (down to 10 % versus 73 % without treatment) with good overall tolerance; prophylactic breast radiotherapy also shows efficacy. In the curative setting, tamoxifen appears more effective than radiotherapy, while surgery remains an invasive fallback option. However, extrapolating results obtained with bicalutamide to second-generation androgen receptor pathway inhibitors remains uncertain due to pharmacological and clinical differences. Gynecomastia could become a major complication of androgen receptor pathway inhibitors monotherapy. To date, tamoxifen and prophylactic breast radiotherapy are the most validated strategies, with the former appearing more effective. Further studies are needed to confirm their specific efficacy and safety in patients treated with androgen receptor pathway inhibitors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GynecomastiaProstatic NeoplasmsAndrogen AntagonistsAndrogen Receptor AntagonistsHumansMaleNitrilesAnilidesTosyl CompoundsTamoxifenReceptors, AndrogenAntineoplastic Agents, Hormonal

Stichwörter der Autor:innen

Cancer de la prostateGynecomastiaGynécomastieHormonothérapieNonsteroidal anti-androgensProstatic neoplasmsRadiotherapyRadiothérapie

Substanzen

NitrilesAnilidesTosyl CompoundsbicalutamideAndrogen AntagonistsTamoxifenAndrogen Receptor AntagonistsReceptors, AndrogenAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France. Electronic address: n.vibert@bordeaux.unicancer.fr.
  • Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France; Université de Genève, rue du Général-Dufour 24, 1211 Genève, Suisse.
  • Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France.
  • Service de radiothérapie, Institut universitaire du cancer de Toulouse-Oncopole, institut Claudius-Regaud, 1, avenue Irène-Joliot-Curie, 31100 Toulouse, France.
  • Service de radiothérapie, institut Bergonié, 229, cour de l'Argonne, 33076 Bordeaux, France; Service de radiothérapie, Amethyst Radiotherapy Group, 65, avenue Foch, 92250 La Garenne-Colombes, France.

Zitieren

APA

Vibert, N., Achard, V., Pouvreau, P., Huck, C., Khalifa, J., & Sargos, P. (2025). Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate. Cancer/Radiothérapie. https://doi.org/10.1016/j.canrad.2025.104665

Vancouver

Vibert N, Achard V, Pouvreau P, Huck C, Khalifa J, Sargos P. Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate. Cancer/Radiothérapie. 2025. doi:10.1016/j.canrad.2025.104665

BibTeX
@article{Vibert2025,
  author = {Vibert, Nassim and Achard, Vérane and Pouvreau, Pierre and Huck, Constance and Khalifa, Jonathan and Sargos, Paul},
  title = {Prise en charge de la gynécomastie à l’ère des inhibiteurs des récepteurs aux androgènes chez les patients atteints de cancer de la prostate},
  journal = {Cancer/Radiothérapie},
  year = {2025},
  doi = {10.1016/j.canrad.2025.104665}
}
Kostenlos starten →